☆ 4.6 Letter

Daratumumab vs pomalidomide for the treatment of relapsed/refractory multiple myeloma: A cost-effectiveness analysis

AMERICAN JOURNAL OF HEMATOLOGY (2019)

Get Full Text
Add to Collection

Journal

AMERICAN JOURNAL OF HEMATOLOGY
Volume 94, Issue 3, Pages E68-E70

Publisher

WILEY
DOI: 10.1002/ajh.25372

Keywords

-

Categories

Hematology

Funding

  1. Celgene
  2. Janssen Pharmaceuticals

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.